031 Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Point-of-Care test

Results Median [IQR] values were 0.1 [0.1-0.1] and 0.87 [0.74-1.03] IU/mL for AXA; 74 [70-81] and 143 [114-206] sec for Hemonox CT, and 44 [39-50] and 72 [58-93] sec for aPTT at T1 and T2 time points, respectively. Hemonox CT strongly correlated with Anti-Xa level spearman r=0.81 (95% CI 0.77-0.84, p<0.0001). When comparing a total of 486 values to discriminate patients with AXA <0.5 IU/mL, the area under the receiver operating curve (AUC) for Hemonox CT was 0.95 ± 0.01 (95% IC; 0.93-0.97; p<0.0001) versus 0.89 ± 0.01 (95% IC; 0.86-0.92; p<0.0001) for aPTT. A threshold Hemonox CT value of 120 sec was associated with a 94.9% (95% CI 91.1-97.4) sensitivity and a 73.3% (95% IC 67.6-78.5) specificity with a likelihood ratio = 3.5 to detect patients with inadequate anti-Xa level (<0.5UI/mL). With this threshold the positive predictive and negative predictive values of Hemonox CT as a diagnosis test were 73.9% (95% IC 68.7-79.0) and 94.78% (95% IC 91.8-97.8) respectively. Conclusion According to the results of this study Hemonox CT appears to be a fast and reliable bedside test that could be used to adjust enoxaparin anticoagulation in PCI.